Core Viewpoint - The company Kang Le Wei Zhi is facing significant liquidity pressure due to ongoing R&D investments and delays in financing, leading to multiple court-ordered consumption restrictions and frozen bank accounts [2][3][4]. Financial Situation - As of December 26, 2025, Kang Le Wei Zhi's total market capitalization was 2.512 billion yuan [2]. - The company reported a net loss of 3.57 billion yuan for the year 2024, with a net asset deficit of 1.686 billion yuan [8]. - By the end of 2024, the company's current liabilities exceeded current assets by 7.32 billion yuan [8]. - For the first three quarters of 2025, the company generated revenue of 127.63 million yuan, with a net loss of 2.29 billion yuan [9]. Legal and Operational Challenges - The company and its legal representative, Tao Ran, have been subjected to multiple consumption restriction orders due to failure to fulfill financial obligations, with amounts involved totaling 19.85 million yuan, 6.6 million yuan, and 7.86 million yuan [3][4]. - As of December 18, 2025, 15 bank accounts belonging to the company and its subsidiaries were frozen, representing 41.67% of their total accounts, with a cumulative frozen amount of 346,900 yuan [5]. R&D and Market Position - Kang Le Wei Zhi specializes in HPV vaccines, with ongoing clinical trials for various products, including a nine-valent HPV vaccine and a fifteen-valent HPV vaccine in collaboration with Chengda Biological [6]. - The HPV vaccine market is highly competitive, with several established players and a decline in vaccine prices due to increased supply [7]. - The company has not yet launched any vaccine products, and its revenue primarily comes from the sale of research reagents, which is relatively small [7]. Future Outlook - The company has submitted an application for a Hong Kong stock listing, but there has been no recent progress [6]. - The inclusion of HPV vaccines in the national immunization program starting November 10, 2025, may intensify competition for Kang Le Wei Zhi's products [7].

Group 1 - The biopharmaceutical sector increased by 0.18% on December 25, with Jindike leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] - Key stocks in the biopharmaceutical sector showed various performance, with Jindike (688670) rising by 4.66% to a closing price of 22.45 [1] Group 2 - The biopharmaceutical sector experienced a net outflow of 307 million yuan from institutional investors, while retail investors saw a net inflow of 359 million yuan [2] - Notable declines included Te Bao Biological (688278), which fell by 3.14% to a closing price of 80.90 [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Wan Ze Co. (000534) achieving a turnover of 488 million yuan [1][2] Group 3 - Jindike (688670) had a net inflow of 25.23 million yuan from institutional investors, while retail investors had a net outflow of 23.95 million yuan [3] - Other stocks like Zhi Xiang Jin Tai (688443) and Shen Zhou Cell (688520) also showed mixed net inflows and outflows from different investor categories [3] - The overall trend indicates a divergence in investor sentiment, with institutional investors pulling back while retail investors increased their positions [2][3]

Core Viewpoint - Beijing Kanglwei Biological Technology Co., Ltd. (Kanglwei) announced that its subsidiary, Kunming Kanglwei, failed to repay a loan of 15.21 million yuan from CITIC Bank but has since settled the debt in full [1] Financial Performance - As of September 2025, Kanglwei's consolidated asset-liability ratio was approximately 78.36%, an increase of 14.16% from 64.20% at the end of 2024 [1] - Current non-current liabilities due within one year amounted to approximately 96.49 million yuan, reflecting a change of 64.75% [1] - Long-term borrowings were approximately 17.28 million yuan, showing a decrease of 81.06% [1] - Lease liabilities were approximately 0.29 million yuan, with a change of -90.91% [1] Company Overview - Established in 2008, Kanglwei is a high-tech enterprise focused on innovative vaccine research and commercialization [2] - The company is a leader in HPV vaccine development in China, offering a comprehensive product portfolio that includes three-valent, nine-valent, and fifteen-valent HPV vaccines [2] - As of September, Kanglwei's R&D expenses accounted for approximately 9263.76% of total operating income, the highest among companies listed on the Beijing Stock Exchange [2]

Group 1 - The company announced that its subsidiary, Kunming Kangle, failed to repay a loan of 15.21 million yuan from CITIC Bank but has since completed the repayment of both principal and interest [1] - The company is actively seeking funds through multiple channels and is enhancing its financial management to ensure timely repayment of future bank loans [1] - The company is committed to taking all necessary measures to support the stable operation of its core business and improve its overall operational status [1] Group 2 - The company and its subsidiaries are involved in litigation and arbitration, leading to the freezing of bank accounts due to asset preservation requests [2] - The total amount involved in litigation and arbitration over the past 12 months is 30.86 million yuan, which accounts for 5.58% of the company's latest audited net assets [2] - As of December 18, 15 bank accounts have been frozen, representing 41.67% of the total number of accounts, with a cumulative frozen amount of 346,900 yuan [2] Group 3 - The freezing of bank accounts has impacted the company's cash flow and payment capabilities for daily operations [3] - The company is in communication with relevant parties and judicial authorities to expedite the unfreezing of accounts through negotiation and settlement [3] - A patent of the company has also been subjected to asset preservation measures due to a labor arbitration case, and the company is facing liquidity pressure due to ongoing R&D investments and slower-than-expected financing progress [3]

本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 证券代码：920575 证券简称：康乐卫士 公告编号：2025-149 北京康乐卫士生物技术股份有限公司 关于子公司偿还银行贷款的公告 公司及子公司正努力通过多渠道筹措资金，加强资金管理，努力保障后续银 行贷款的按期偿还。同时，公司将采取一切必要措施，全力支持核心业务的稳定 运营，改善公司整体经营状况。 公司将按照相关规定及时履行信息披露义务，敬请广大投资者注意投资风险。 特此公告。 北京康乐卫士生物技术股份有限公司 董事会 2025 年 12 月 19 日 一、子公司银行贷款偿还进展情况 2025 年 12 月 18 日，北京康乐卫士生物技术股份有限公司（以下简称"公 司"）披露了《关于公司未按期偿还银行贷款及部分银行账户被冻结的公告》（公 告编号：2025-148），公司控股子公司康乐卫士（昆明）生物技术有限公司（以下 简称"昆明康乐"）尚未按期偿还中信银行股份有限公司昆明分行的贷款金额 1,521.17 万元。 上述事项发生后，公司及控股子公司昆明康 ...

Group 1 - The stock of Kang Le Wei Shi (920575.BJ) closed at 8.69 yuan, down 14.38%, reaching a new low of 8.55 yuan, indicating it is currently in a state of decline [1] - Kang Le Wei Shi was listed on the Beijing Stock Exchange on March 15, 2023, with an initial offering price of 42.00 yuan, but it opened below this price on the first day, closing at 35.52 yuan, a drop of 15.43% [1] - The company issued 7,000,000 shares (excluding the overallotment option) and 8,050,000 shares (if the overallotment option is fully exercised), with CITIC Securities as the lead underwriter [1] Group 2 - The total amount of funds raised by Kang Le Wei Shi before the exercise of the overallotment option was 29,400,000 yuan, with net proceeds of 26,662,410 yuan after deducting issuance costs of 2,737,590 yuan [1] - The net proceeds were 3,337,590 yuan less than the original plan of 30,000,000 yuan, which was intended for HPV vaccine research and the construction of a production base in Kunming [1] - The total issuance costs amounted to 2,737,590 yuan (before the overallotment option) and 3,008,020 yuan (if the overallotment option is fully exercised), with underwriting fees to CITIC Securities and Guotai Junan totaling 1,902,830 yuan (before overallotment) [2]

股权质押的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、股权质押概述 （一）基本情况 证券代码：920575 证券简称：康乐卫士 公告编号：2025-145 北京康乐卫士生物技术股份有限公司 公司股东天狼星控股集团有限公司质押 2,000,000 股，占公司总股本 0.71%。 在本次质押的股份中，2,000,000 股为有限售条件股份，0 股为无限售条件股份。 质押期限为 2025 年 12 月 15 日起至业务结清止。质押股份用于融资性质押，质 押权人为陈华，质押权人与质押股东不存在关联关系。质押股份已在中国结算办 理质押登记。 （二）本次股权质押对公司的影响 所涉及的股份是实际控制人控制的股份。 包括本次质押股份在内，如果全部在质股份被行权不会导致公司控股股东或 者实际控制人发生变化。 本次股权质押不会对公司生产经营等产生影响。 二、股权质押所涉股东情况 （一）质押具体情况 股东姓名（名称）：天狼星控股集团有限公司 是否为控股股东、实际控制人及其一致行动人：是 持股份总数及占比：60, ...

证券代码：920575 证券简称：康乐卫士 公告编号：2025-146 北京康乐卫士生物技术股份有限公司 高级管理人员变动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责任。 一、高级管理人员任命的基本情况 北京康乐卫士生物技术股份有限公司（以下简称"公司"）董事会近日收到首席财 务官董微女士的书面辞职报告，董微女士因个人原因，申请辞去公司首席财务官职务， 离任后不再担任公司及其控股子公司其它职务。 因原首席财务官辞职，为完善公司治理结构，根据《公司法》《北京证券交易所股 票上市规则》及《公司章程》等相关规定，公司于 2025 年 12 月 18 日召开第五届董事 会第十四次会议，审议通过《关于聘任公司首席财务官的议案》，经公司首席执行官提 名，并经公司提名委员会及审计委员会审查，公司董事会拟聘任王泽学先生为公司首席 财务官，任职期限自本次董事会审议通过之日起至第五届董事会届满之日止。 聘任王泽学先生为公司首席财务官，任职期限至第五届董事会任期届满之日止，自 2025 年 12 月 18 日起生效。该人员 ...

北京康乐卫士生物技术股份有限公司 关于公司未按期偿还银行贷款及部分银行账户被冻结的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 北京康乐卫士生物技术股份有限公司（以下简称"公司"）目前尚未实现商 业化，营运资金主要来源于外部融资。因持续研发投入及融资进度未及预期，公 司面临阶段性流动性压力。近期，公司控股子公司康乐卫士（昆明）生物技术有 限公司（以下简称"昆明康乐"）出现个别债务未能如期偿还的情形；此外，公 司及子公司涉及诉讼仲裁，并因部分诉讼仲裁被申请财产保全导致银行账户被冻 结。现将有关情况公告如下： 一、未按期偿还银行贷款情况 截至本公告披露日，昆明康乐未按期偿还中信银行股份有限公司昆明分行的 贷款本息金额为 2,021.17 万元，现已归还 500.00 万元，尚未偿还 1,521.17 万元， 占公司最近一期经审计净资产的 2.75%。该笔贷款担保方式为保证+抵押+质押担 保，具体包括：公司提供连带责任保证担保，公司控股子公司云南滇中立康实业 发展有限公司名下土地抵押及机器设备抵押担保 ...

证券代码：920575 证券简称：康乐卫士 公告编号：2025-147 北京康乐卫士生物技术股份有限公司 第五届董事会第十四次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2025 年 12 月 18 日 4.发出董事会会议通知的时间和方式：2025 年 12 月 15 日以邮件和电话方式 发出 5.会议主持人：董事长刘永江先生 6.会议列席人员：部分高级管理人员 7.召开情况合法合规的说明： 本次会议的召集、召开、议案审议程序符合相关法律、行政法规、部门规章、 规范性文件和《公司章程》等有关规定。 （二）会议出席情况 会议应出席董事 9 人，出席和授权出席董事 9 人。 二、议案审议情况 （一）审议通过《关于聘任公司首席财务官的议案》 1.议案内容： 2.会议召开地点：公司会议室 3.会议召开方式：现场与通讯相结合的方式 该议案不涉及关联交易事项，无需回避表决。 4.提交股东会表决情况： 本议案无需提交股东会审议。 （二）备 ...